Provided by Tiger Fintech (Singapore) Pte. Ltd.

CMS

14.170
+0.1801.29%
Volume:6.37M
Turnover:89.96M
Market Cap:34.57B
PE:19.39
High:14.340
Open:14.100
Low:13.830
Close:13.990
52wk High:15.630
52wk Low:6.523
Shares:2.44B
HK Float Shares:2.44B
Volume Ratio:1.16
T/O Rate:0.26%
Dividend:0.30
Dividend Rate:2.11%
EPS(LYR):0.731
ROE:9.91%
ROA:5.58%
PB:1.86
PE(LYR):19.39
PS:4.02

Loading ...

Exclusive Novartis Ophthalmology Deal Might Change The Case For Investing In China Medical System Holdings (SEHK:867)

Simply Wall St.
·
Nov 04

Are China Medical System Holdings Limited's (HKG:867) Mixed Financials Driving The Negative Sentiment?

Simply Wall St.
·
Nov 01

China Medical System (00867) Issues Monthly Return for October 2025

Bulletin Express
·
Oct 31

CMS (00867): China's NMPA Accepts Marketing Application for Long-Acting Anti-IL-4Rα Monoclonal Antibody for Atopic Dermatitis

Stock News
·
Oct 30

China Medical System Gets NMPA Acceptance for Atopic Dermatitis Drug Application

Reuters
·
Oct 30

China Medical System - Nda for Atopic Dermatitis Indication of Long-Acting Anti-Il-4Ra Humanized Monoclonal Antibody Injection Accepted in China

THOMSON REUTERS
·
Oct 30

CMS (867.HK; 8a8.SG) Signed a Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

THOMSON REUTERS
·
Oct 27

China Medical System Enters Distribution Contract with Novartis Pharma Services for Ophthalmic Drugs

MT Newswires
·
Oct 27

BRIEF-China Medical System Says Entered Distribution Agreement With Novartis Pharma Services AG

Reuters
·
Oct 27

China Medical System Holdings Limited (CMS) Announces Distribution Agreement with Novartis for Lucentis® and Beovu®

Bulletin Express
·
Oct 27

China Medical System - Signing a Distribution Agreement for Ophthalmic Drugs Lucentis and Beovu

THOMSON REUTERS
·
Oct 27

CMS (00867) Enters Distribution Agreement with Novartis for Ophthalmic Drugs Lucentis® and Beovu®

Stock News
·
Oct 27

China Medical System - Agreement for Ranibizumab Injection and Brolucizumab Injection

THOMSON REUTERS
·
Oct 27

China Medical System - Entered Into Distribution Agreement With Novartis Pharma Services Ag

THOMSON REUTERS
·
Oct 27

Does MG-K10’s COPD Trial Approval Change the Bull Case for China Medical System Holdings (SEHK:867)?

Simply Wall St.
·
Oct 13

CMS (00867) Receives Clinical Trial Approval for Class 1 New Drug MG-K10 Humanized Monoclonal Antibody Injection for Chronic Obstructive Pulmonary Disease Indication

Stock News
·
Sep 30

China Medical System Holdings Ltd. Receives NMPA Approval to Begin Clinical Trials of MG-K10 Monoclonal Antibody Injection for COPD

Reuters
·
Sep 30

China Medical System Holdings Ltd - Announces Mg-K10 Drug Trial Approval by Nmpa

THOMSON REUTERS
·
Sep 30

China Medical System Unit Receives Regulatory Nod to Conduct Phase 3 Trial of Skin Drug

MT Newswires Live
·
Sep 29

Hong Kong Stock Early Insight | Eight Departments Issue Guidelines to Promote Non-Ferrous Metals Industry Stable Growth, Hong Kong to Build Global Fixed Income and Currency Products Hub

Stock News
·
Sep 29